FibroGen (NASDAQ:FGEN) Earns Hold Rating from Analysts at StockNews.com

StockNews.com initiated coverage on shares of FibroGen (NASDAQ:FGEN) in a report issued on Friday. The firm issued a hold rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright restated a “buy” rating and set a $10.00 target price on shares of FibroGen in a report on Thursday, February 20th.

FibroGen Stock Up 2.9 %

NASDAQ:FGEN opened at $0.44 on Friday. The stock has a market cap of $44.27 million, a P/E ratio of -0.36 and a beta of 0.82. The firm’s fifty day simple moving average is $0.51 and its 200 day simple moving average is $0.43. FibroGen has a twelve month low of $0.18 and a twelve month high of $2.80.

Institutional Trading of FibroGen

A number of hedge funds have recently modified their holdings of FGEN. JPMorgan Chase & Co. boosted its holdings in shares of FibroGen by 430.7% during the 3rd quarter. JPMorgan Chase & Co. now owns 1,673,555 shares of the biopharmaceutical company’s stock valued at $668,000 after buying an additional 1,358,194 shares in the last quarter. Renaissance Technologies LLC raised its position in shares of FibroGen by 80.4% in the 4th quarter. Renaissance Technologies LLC now owns 1,358,712 shares of the biopharmaceutical company’s stock worth $719,000 after purchasing an additional 605,572 shares during the last quarter. Mackenzie Financial Corp raised its position in shares of FibroGen by 416.6% in the 4th quarter. Mackenzie Financial Corp now owns 546,959 shares of the biopharmaceutical company’s stock worth $290,000 after purchasing an additional 441,083 shares during the last quarter. Squarepoint Ops LLC purchased a new position in shares of FibroGen in the 4th quarter worth about $205,000. Finally, Two Sigma Advisers LP raised its position in shares of FibroGen by 18.3% in the 4th quarter. Two Sigma Advisers LP now owns 878,400 shares of the biopharmaceutical company’s stock worth $465,000 after purchasing an additional 135,600 shares during the last quarter. Institutional investors own 72.71% of the company’s stock.

FibroGen Company Profile

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.